FOCUS on New Drug Approvals. The FDA just announced approval of Revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children with relapsed or refractory acute myeloid leukemia (AML) with NPM1 gene mutations. Revumenib was first approved one year ago for patients with AML harboring a KMT2A mutation. While KMT2A mutations are somewhat rare in AML, NPM1 mutations are much more common. With this new approval, up to 40% of patients with AML will have access to Revumenib as a treatment option. Focus Biomolecules can supply Revumenib for research applications. Contact us for more information.
